Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.35 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20928768 | 0.80 | ACHE (0.36) | ACHEL3MBTL1ACVR2ATGFBR2FGFR2 | |
| SCHEMBL31278345 | 0.80 | CDK1 (0.36) | ACHEL3MBTL1ACVR2ATGFBR2FGFR2 | |
| SCHEMBL23618526 | 0.79 | KMT2A (0.40) | ACHEL3MBTL1ALDH1A1GAA | |
| SCHEMBL19629678 | 0.78 | FGFR2 (0.36) | ACHEL3MBTL1ACVR2ATGFBR2ALDH1A1 | |
| SCHEMBL19769065 | 0.78 | IKBKB (0.39) | ACHEL3MBTL1ACVR2ATGFBR2ALDH1A1 | |
| SCHEMBL25791763 | 0.78 | HPGD (0.38) | ACHEL3MBTL1ACVR2ATGFBR2FGFR2 | |
| SCHEMBL26549574 | 0.78 | CYP1A2 (0.35) | ACHEL3MBTL1ACVR2ATGFBR2ALDH1A1 | |
| SCHEMBL25791543 | 0.76 | FGFR2 (0.35) | ACHEL3MBTL1ACVR2ATGFBR2ALDH1A1 | |
| SCHEMBL19865907 | 0.75 | NPC1 (0.42) | L3MBTL1ALDH1A1GAA | |
| SCHEMBL9963325 | 0.75 | PLAU (0.46) | ACHEPDGFRBPDGFRAPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200317705-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | ACHE 4457/4885L3MBTL1 4011/4885ACVR2A 1069/4885 |
| US-20200317705-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | ACHE 4457/4885L3MBTL1 4011/4885ACVR2A 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.